Lung transplantation

Randall C. Starling, MD, MPH Receives 2023 HFSA Lifetime Achievement Award for His Contributions to the Field of Heart Failure

Retrieved on: 
Thursday, September 14, 2023
Cleveland Clinic, Vice, University, Alpha and Omega, Heart failure, Education, Internal medicine, Temple University, Heart Failure Society of America, Lung transplantation, NIH, American College of Cardiology, Case Western Reserve University, Research, Journal of Cardiac Failure, Alpha Omega Alpha, National Institutes of Health, Associate, Bangladesh Technical Education Board, Science, OSU, University of Pittsburgh Medical Center, Public health, Journal, Publishing, Overmyer Network, Scientific programming language, Cardiology, Huntington Convention Center of Cleveland, Master, Biology, American College, MPH, Wilfrid Sellars, International Society, Medical device, Dentistry, MD, Medicine

The award will be presented to Dr. Starling at the HFSA Annual Scientific Meeting on Saturday, October 7 in Cleveland, Ohio.

Key Points: 
  • The award will be presented to Dr. Starling at the HFSA Annual Scientific Meeting on Saturday, October 7 in Cleveland, Ohio.
  • As an internationally recognized pioneer and expert in the field of heart failure, this prestigious award will pay tribute to his exemplary career in heart failure research, publishing, mentorship and leadership.
  • Dr. Starling served as President of HFSA in 2018-2019 and has been an active member since its inception in 1995.
  • Dr. Starling joins an elite list of current and past Lifetime Achievement Award winners with this year's recognition.

Rencofilstat Produces Positive Outcomes in Translational Study on Idiopathic Pulmonary Fibrosis

Retrieved on: 
Thursday, September 14, 2023
Antigen, Idiopathic disease, Nidogen, Drug development, Idiopathic pulmonary fibrosis, NASH, Culture, E pluribus unum, MHC, Cancer, Proteomics, Cathepsin B, TIMP3, Chronic obstructive pulmonary disease, Asporin, Lung transplantation, Protein, Keratin, Patient, Fatty liver disease, Integrin, Artificial intelligence, Conditional sentence, HEPA, IPF, Pharmaceutical industry, Vaccine, Dietary supplement

EDISON, N.J., Sept. 14, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“NASH”), fibrotic diseases, hepatocellular carcinoma (“HCC”), and other chronic diseases, today announced positive results from a translational research study in which Hepion’s lead drug candidate, rencofilstat, was administered to diseased human lung tissue from patients with idiopathic pulmonary fibrosis (“IPF”).

Key Points: 
  • In this study, FibroFind Ltd. (Newcastle, UK) obtained diseased lung tissue from two individuals undergoing lung transplantation for end-stage IPF, a deadly fibrotic lung disease.
  • Precision cut lung slices (PCLuS) were made and individually incubated in culture with rencofilstat, nintedanib, pirfenidone, or combinations of the compounds for four days.
  • Quantitative proteomic characterization of lung tissue in idiopathic pulmonary fibrosis.
  • Quantitative proteomic characterization of the lung extracellular matrix in chronic obstructive pulmonary disease and idiopathic pulmonary fibrosis.

CareDx Advances Global Transplant Patient Care at ESOT Congress 2023

Retrieved on: 
Thursday, September 14, 2023
Biotechnology, Surgery, Hospitals, Health, Clinical Trials, Abstract, DNA, Paris Institute for Advanced Study, Comparison, Nucleic acid thermodynamics, Transplant, Doctor of Philosophy, Necker–Enfants Malades Hospital, Organ transplantation, Teaching hospital, University Hospital of Zürich, Associate, Congress, Plasma, Lung transplantation, Nephrology, Local, MD, Patient, Risk, Medical University of Vienna, UZ Leuven, Harbin Medical University, Paris, European Society for Primary Immunodeficiencies, Caregiver, Dentistry, Medical device, Epidemiology

CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced a leading presence at the 2023 European Society for Organ Transplantation (ESOT) Congress taking place September 17-20, 2023, in Athens, Greece.

Key Points: 
  • CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced a leading presence at the 2023 European Society for Organ Transplantation (ESOT) Congress taking place September 17-20, 2023, in Athens, Greece.
  • CareDx is hosting an educational symposium for medical professionals demonstrating the clinical utility of AlloSeq cfDNA.
  • “We are proud to attend ESOT Congress 2023, a preeminent European transplant conference, and share the latest data demonstrating the use of AlloSeq cfDNA,” said Reg Seeto, CEO and President of CareDx.
  • CareDx will review the latest data on AlloSeq cfDNA during an ESOT Congress 2023 Industry Satellite Symposium titled, “Adopting dd-cfDNA for Solid Organ Surveillance: Raising the Standards of Transplant Care.” The symposium will be held live and streamed virtually on ESOT’s Congress platform on Sunday, September 17, 2023.

Natera’s Prospera™ Lung Transplant Assessment Test Granted Medicare Coverage

Retrieved on: 
Wednesday, August 16, 2023
Science, Cardiology, Other Science, Research, Surgery, Health, Genetics, Clinical Trials, DNA, Medicaid, CMS, CLAD, Lung transplantation, Nucleic acid thermodynamics, Survival, Houston Methodist Hospital, Medicare, Medicine, Patient, Centers for Medicare & Medicaid Services, Mortality, Nursing care plan, AR, NTRA, Biopsy, Dentistry, Natera

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing, today announced that it has received confirmation that its Prospera Lung donor-derived cfDNA (dd-cfDNA) transplant assessment test has met coverage requirements from the Centers for Medicare & Medicaid Services’ (CMS) Molecular Diagnostics Services Program (MolDX).

Key Points: 
  • Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing, today announced that it has received confirmation that its Prospera Lung donor-derived cfDNA (dd-cfDNA) transplant assessment test has met coverage requirements from the Centers for Medicare & Medicaid Services’ (CMS) Molecular Diagnostics Services Program (MolDX).
  • The MolDX technology assessment program has determined that Prospera Lung will be covered under the existing Medicare Local Coverage Determination for Molecular Testing for Solid Organ Allograft Rejection for use in the surveillance setting in lung transplant patients.
  • This blinded, prospective study analyzed Prospera Lung in connection with various complications from lung transplantation, including AR, CLAD and allograft infection.
  • “Medicare’s decision enables broad access to the Prospera Lung test and represents a significant win for lung transplant patients and the field of transplant monitoring,” said Bernie Tobin, general manager of organ health at Natera.

CareDx’s HeartCare Multimodality Service Receives Medicare Coverage for Heart Transplant Surveillance

Retrieved on: 
Wednesday, August 2, 2023
Research, Surgery, Genetics, Clinical Trials, Cardiology, Health Insurance, Biometrics, Health, Science, DNA, Biopsy, Stanford University, Embraer EMB 314 Super Tucano, GEP, Heart, Lung transplantation, Section, Palmetto, Biomarker, USC, Medicare, Journal, Publication, MD, Patient, Medicine, Heart failure, American College, Caregiver, FDA, International Society, International Society for Heart and Lung Transplantation, Pharmaceutical industry, Dentistry, Medical imaging

CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced Medicare coverage for HeartCare, a multimodality testing service that includes both AlloMap® Heart and AlloSure® Heart, in a given patient encounter, for heart transplant surveillance.

Key Points: 
  • CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced Medicare coverage for HeartCare, a multimodality testing service that includes both AlloMap® Heart and AlloSure® Heart, in a given patient encounter, for heart transplant surveillance.
  • AlloMap Heart and AlloSure Heart are also covered by Medicare individually.
  • “Today is a major milestone for heart transplant care and for the use of multimodality technologies to improve patient outcomes with HeartCare,” said Reg Seeto, CEO and President of CareDx.
  • I want to thank MolDX for recognizing the critical clinical value of multimodality in heart transplant surveillance.”
    “Medicare’s coverage of HeartCare reflects the growing scientific evidence supporting its use for routine graft surveillance in lieu of a biopsy.

Submission Site for ISHLT 2024 Annual Meeting Abstracts Now Open

Retrieved on: 
Tuesday, August 1, 2023
Call, Heart, Abstract (summary), International Society for Heart and Lung Transplantation, Lung transplantation, Research, Doctor of Philosophy, Nursing, International Society, Dentistry, MD

Chicago, IL, Aug. 01, 2023 (GLOBE NEWSWIRE) -- The International Society for Heart and Lung Transplantation (ISHLT) has opened abstract submissions for its 44th Annual Meeting & Scientific Sessions in Prague, Czech Republic on 10-13 April, 2024.

Key Points: 
  • Chicago, IL, Aug. 01, 2023 (GLOBE NEWSWIRE) -- The International Society for Heart and Lung Transplantation (ISHLT) has opened abstract submissions for its 44th Annual Meeting & Scientific Sessions in Prague, Czech Republic on 10-13 April, 2024.
  • “Abstracts and presentations are the cornerstones of every ISHLT meeting,” said ISHLT2024 Scientific Program Chair, Göran Dellgren, MD, PhD.
  • The ISHLT welcomes submissions from all specialists engaged in treating advanced heart and lung disease, particularly those working on novel therapies.
  • For more information about ISHLT2024, and to see full details on the Call for Abstracts, visit ishlt.org/ishlt2024 .

CareDx’s AlloSure Lung dd-cfDNA Testing Service Receives Medicare Coverage for Lung Transplant Rejection Monitoring

Retrieved on: 
Tuesday, July 11, 2023
Biotechnology, Surgery, Health, Genetics, Health Technology, Infection, ACR, DNA, Lung transplantation, Transplant, AMR, Lung, Medicare, Patient, Physician, Kidney, Caregiver, Dentistry, Medical imaging, Brigham

CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that CareDx’s AlloSure® Lung donor-derived cell-free DNA (dd-cfDNA) molecular testing service has received Medicare coverage.

Key Points: 
  • CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that CareDx’s AlloSure® Lung donor-derived cell-free DNA (dd-cfDNA) molecular testing service has received Medicare coverage.
  • The MolDX technology assessment program has determined that AlloSure Lung will be covered under the existing Medicare Local Coverage Determination for Molecular Testing for Solid Organ Allograft Rejection for use in the surveillance setting in lung transplant patients, effective May 9, 2023.1
    “CareDx was the first to receive MolDX coverage of dd-cfDNA with AlloSure for kidney and heart transplant patients, and we are now proud to be the first approved for lung transplant patients.
  • We are 100% committed to transplant patients and today’s milestone approval represents a monumental day for lung transplant patients,” said Reg Seeto, CEO and President of CareDx.
  • Lung transplant patients have one of the lowest median survivals of any solid organ transplant recipient, with a five-year survival rate of approximately 53 percent.8 Introduced in October 2021, AlloSure Lung has already been adopted in over 60 percent of lung transplant centers.7

Arbutus Appoints Two New Executives

Retrieved on: 
Monday, July 10, 2023
KRYS, Employment, University, Therapy, General counsel, Willamette University College of Law, HIV, Virology, Liz, Van Sweringen railroad holdings, Infection, Drug, Viral, Bristol Myers Squibb, Koch Industries, Doctor of Philosophy, Bates College, Assistant, BMY, Hospital of the University of Pennsylvania, Arbutus, Lung transplantation, Medical director, Patent, MD, Patient, Internal medicine, Oklahoma Office of the Chief Medical Examiner, Corporation, RNA interference, Hospital, Blank Rome, HCV, Hampden–Sydney College, HBV, NYSE, Behavioral neuroscience, Compensated emancipation, Pharmaceutical industry, Neuroscience, Medicine

WARMINSTER, Pa., July 10, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced the appointment of Dr. Karen Sims as Chief Medical Officer and Mr. Christopher Naftzger as General Counsel and Chief Compliance Officer. Mr. Naftzger succeeds Dr. Elizabeth Howard who will continue in an advisory role with respect to the on-going patent infringement litigations. Both Dr. Sims and Mr. Naftzger will report directly to William Collier, Arbutus President and Chief Executive Officer, effective immediately.

Key Points: 
  • Both Dr. Sims and Mr. Naftzger will report directly to William Collier, Arbutus President and Chief Executive Officer, effective immediately.
  • “Karen has played an integral role in the clinical development of AB-729, our lead RNAi therapeutic, during her six-year tenure at Arbutus, and has continued to advance our pipeline of HBV programs.
  • Prior to joining Arbutus, Dr. Sims held multiple positions during her seven-year tenure at Bristol-Myers Squibb (NYSE: BMY).
  • Christopher Naftzger joins Arbutus with more than 25 years of legal experience, including over a decade of experience serving as senior in-house counsel with life science companies.

RENOWNED PEDIATRIC HEART SURGEON JOINS MONTEFIORE EINSTEIN

Retrieved on: 
Monday, July 10, 2023
Boston Children's Hospital, Heart, Surgeon, University, Mathematics, Extracorporeal membrane oxygenation, Cone Health Women's Hospital, ECMO, Ventricular septal defect, Cardiology, Harvard University, Harvard Medical School, Social, Hospital of the University of Pennsylvania, Lung transplantation, CHAM, Pharmacist, Montefiore, Professor, MD, Patient, Division, Nursing, Fellow, Heart transplantation, Infant, Hospital, General surgery, Dentistry, Cardiothoracic surgery

NEW YORK, July 10, 2023 /PRNewswire/ -- Ibrahim Abdullah, M.D., has been recruited by Dr. Robert Michler to serve as the new Chief of the Division of Pediatric Cardiothoracic Surgery and Director of Pediatric Heart Transplantation & Pediatric Extracorporeal Membrane Oxygenation (ECMO) in the Department of Cardiothoracic & Vascular Surgery and the Montefiore Einstein Center for Heart & Vascular Care. He will also serve as Co-Director of the Pediatric Heart Center at the Children's Hospital at Montefiore (CHAM).

Key Points: 
  • NEW YORK, July 10, 2023 /PRNewswire/ -- Ibrahim Abdullah, M.D., has been recruited by Dr. Robert Michler to serve as the new Chief of the Division of Pediatric Cardiothoracic Surgery and Director of Pediatric Heart Transplantation & Pediatric Extracorporeal Membrane Oxygenation (ECMO) in the Department of Cardiothoracic & Vascular Surgery and the Montefiore Einstein Center for Heart & Vascular Care .
  • He will also serve as Co-Director of the Pediatric Heart Center at the Children's Hospital at Montefiore (CHAM).
  • This includes newborn heart surgery, complex anatomical conditions, lifesaving heart transplants and the management of children who need ECMO, in which a machine replaces the function of the heart and lungs when a patient's body is unable to do it themselves.
  • This is an exciting new chapter for Montefiore Einstein and for the community we serve."

Konica Minolta Announces Significant Expansion of Dynamic Digital Radiography Across Multiple Facility Types and Clinical Care Areas

Retrieved on: 
Monday, July 10, 2023
Amos, Barium, Partnership, DDR, Workflow, Patient satisfaction, Pelvis, Anatomy, Claustrophobia, Doctor of Philosophy, Stomach, Lung transplantation, MRI, Motion, Konica Minolta, Hospital, Patient, Digital radiography, Emory Healthcare, Hearing, Automatic exposure control, MSK, Fluoroscopy, Edmond, Injury, Health, Alta Bates Summit Medical Center, Medical imaging, Radiology

Unlike fluoroscopy, DDR is a series of individual digital X-ray images acquired at high speed and low doses, allowing the visualization of anatomy in motion.

Key Points: 
  • Unlike fluoroscopy, DDR is a series of individual digital X-ray images acquired at high speed and low doses, allowing the visualization of anatomy in motion.
  • DDR has broad utilization across multiple clinical care specialties, including pulmonary, musculoskeletal, lung transplantation, swallowing studies and more, and is being used for both contrast and non-contrast studies.
  • Greg Miner, Appleton Area Health Chief Executive Officer, says, “To bring this type of diagnostic care to Appleton is truly remarkable.
  • DDR is the type of technology you would expect to find in only large metropolitan areas in our region.